

CIN: L27100TG1989PLC010122

**ZENOTECH LABORATORIES LIMITED**

**Registered Office & Factory:**

Survey No.250 -252

Turkapally Village, Genome Valley Road,

Shamirpet Mandal,

Medchal-Malkajgiri Dist.,

Turkapallyadaram,

Hyderabad - 500 101 Telangana, India.

Tel: +91 90320 44584/ 585

Email: info@zenotech.co.in

www.zenotechlab.com

Date: April 29, 2026

**BSE Limited**

Corporate Relationship Dept.,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

**Scrip Code: 532039**

**Sub: Outcome of the Board Meeting held today, i.e., April 29, 2026**

---

Further to our communication dated April 23, 2026, this is to inform that the Meeting of the Board of Directors of the Company ("Board") was held today, i.e., April 29, 2026, which commenced at 11:30 A.M. and concluded at 3:50 P.M. IST.

The Board has, *inter-alia*, approved the Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026, pursuant to Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 (Listing Regulations), along with the Auditor's Report thereon and Declaration under Regulation 33(3)(d) of Listing Regulations are annexed herewith.

For **ZENOTECH LABORATORIES LIMITED**

(Abdul Gafoor Mohammad)

**Company Secretary & Compliance Officer**

ICSI Membership No. A22331

Encl: as above

## ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal, Medchal-Malkajgiri District, Hyderabad - 500101, Telangana

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Standalone audited financial results for the quarter and year ended March 31, 2026

		(Rs in lakhs, except earnings per share)				
Sl. No.	Particulars	Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		Audited*	Unaudited	Audited*	Audited	Audited
I	Revenue from operations	886.50	1,182.60	1,111.32	3,956.20	3,897.57
II	Other operating income	101.56	102.76	101.77	405.16	407.14
III	Other Income	59.65	42.39	49.32	230.90	154.86
IV	<b>Total Income (I+II+III)</b>	<b>1,047.71</b>	<b>1,327.75</b>	<b>1,262.41</b>	<b>4,592.26</b>	<b>4,459.57</b>
V	<b>Expenses</b>					
	a) Cost of materials consumed	-	-	42.75	-	84.02
	b) Purchase of Stock-in-Trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	d) Employee benefit expenses	416.63	402.17	323.28	1,552.79	1,237.78
	e) Depreciation and amortization expense	175.80	179.97	172.69	711.34	696.01
	f) Other expenses	554.24	456.78	400.14	1,889.72	1,564.89
	<b>Total expenses</b>	<b>1,146.67</b>	<b>1,038.92</b>	<b>938.86</b>	<b>4,153.85</b>	<b>3,582.70</b>
VI	<b>Profit/(Loss) before exceptional items and tax (IV-V)</b>	<b>(98.96)</b>	<b>288.83</b>	<b>323.55</b>	<b>438.41</b>	<b>876.87</b>
VII	Exceptional items (Refer Note - 6 & 9)	5.41	(29.89)	(4.88)	(19.51)	192.32
VIII	<b>Profit/(Loss) before tax (VI-VII)</b>	<b>(93.55)</b>	<b>258.94</b>	<b>318.67</b>	<b>418.90</b>	<b>1,069.19</b>
IX	Tax expense					
	a) Current tax	-	-	190.49	-	190.49
	b) Prior period tax	239.42	-	58.84	48.93	58.84
	c) Deferred tax	(17.89)	66.38	(53.64)	477.18	258.57
	<b>Total tax expense (IX)</b>	<b>221.53</b>	<b>66.38</b>	<b>195.69</b>	<b>526.11</b>	<b>507.90</b>
X	<b>Profit/(Loss) for the period (VIII-IX)</b>	<b>(315.08)</b>	<b>192.56</b>	<b>122.98</b>	<b>(107.21)</b>	<b>561.29</b>
XI	Other comprehensive Income					
	a) Items that will not be reclassified to profit or loss					
	Re - measurement of the defined benefit obligations	8.02	(0.59)	0.51	6.24	(2.37)
	Less: Income tax	(2.02)	0.15	(0.15)	(1.57)	0.69
	b) Items that will be reclassified to profit or loss	-	-	-	-	-
	Less: Income tax	-	-	-	-	-
	<b>Total Other comprehensive income (a-b)</b>	<b>6.00</b>	<b>(0.44)</b>	<b>0.36</b>	<b>4.67</b>	<b>(1.68)</b>
XII	<b>Total comprehensive income for the period (X+/-XI)</b>	<b>(309.08)</b>	<b>192.12</b>	<b>123.34</b>	<b>(102.54)</b>	<b>559.61</b>
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i e Other equity				3,409.05	3,510.02
XV	Earnings: (loss) per share (of ₹ 10 - each) (not annualised)					
	a) Basic	(0.52)	0.32	0.20	(0.18)	0.92
	b) Diluted	(0.52)	0.32	0.20	(0.18)	0.92

\* The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.

See accompanying notes to the financial results



**ZENOTECH LABORATORIES LIMITED**

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal, Medchal-Malkajgiri District, Hyderabad - 500101, Telangna  
Phone:+91 40 23480430 / 35 www.zenotechlab.com

**Standalone Balance sheet as at March 31, 2026**

Rs in Lakhs

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>(1) Non current assets</b>		
(a) Property, plant and equipment	6,228 98	6,086 73
(b) Capital work-in-progress	360 33	357 33
(c) Financial assets		
(i) Investments	-	-
(ii) Others	125 82	135 83
(d) Deferred tax assets (net)	-	394 04
(e) Income tax assets	283 20	512 04
(f) Other non-current assets	13 09	18 14
<b>Total non - current assets</b>	<b>7,011 42</b>	<b>7,505 00</b>
<b>(2) Current assets</b>		
(a) Financial assets		
(i) Trade receivables	877 68	745 43
(ii) Cash and cash equivalents	3,028 93	2,657 51
(iii) Bank balances other than above	13 49	12 71
(iv) Other financial asset	143 04	119 62
(b) Other current assets	40 79	44 08
<b>Total current assets</b>	<b>4,103 93</b>	<b>3,579 35</b>
<b>TOTAL ASSETS</b>	<b>11,115.35</b>	<b>11,084.35</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	6,103 06	6,103 06
(b) Other equity	3,409 05	3,510 02
<b>Total equity</b>	<b>9,512 11</b>	<b>9,613 08</b>
<b>LIABILITIES</b>		
<b>(1) Non-current Liabilities</b>		
(a) Financial liabilities		
(i) Other financial liabilities	97 25	87 98
(b) Other non current liabilities	1 88	9 44
(c) Provisions	215 33	133 85
(d) Deferred tax liabilities (net)	83 14	-
<b>Total non - current liabilities</b>	<b>397 60</b>	<b>231 27</b>
<b>(2) Current Liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro and small enterprises	51 81	61 65
(b) Total outstanding dues other than above	317 83	190 71
(ii) Other financial liabilities	309 35	283 15
(b) Other current liabilities	78 64	136 68
(c) Provisions	448 01	445 39
(d) Current tax liabilities (net)	-	121 53
<b>Total current liabilities</b>	<b>1,205 64</b>	<b>1,240 00</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>11,115.35</b>	<b>11,084.35</b>



Zenotech Laboratories Limited		Rs in Lakhs	
Standalone Cash flow statement for the Year ended March 31, 2026		For the Year ended March 31, 2026	For the Year ended March 31, 2025
<b>A. Cash flows from operating activities</b>			
Profit/(loss) before taxation		418.90	1,069.19
<b>Adjustments for:</b>			
Depreciation and amortisation		711.34	696.01
Amounts written back		10.27	(194.01)
Unrealised foreign exchange loss, net		-	1.77
Interest income		(166.49)	(140.90)
<b>Operating cash flows before working capital changes</b>		<b>974.02</b>	<b>1,432.06</b>
<b>Changes in Working Capital:</b>			
(Increase)/ decrease in trade receivables		(132.25)	(420.49)
(Increase)/ decrease in inventories		-	84.02
(Decrease)/ increase in trade payables		126.52	(75.14)
(Increase)/ decrease in other financial assets		(40.88)	40.39
(Increase)/ decrease in current non financial assets		-	-
(Increase)/ decrease in non-current financial assets		10.01	(0.90)
(Increase)/ decrease in non-current assets		9.08	4.60
(Increase)/ decrease in other current assets		3.29	34.66
(Decrease)/ increase in provisions		72.54	15.85
(Decrease)/ increase in other financial liabilities		(1.69)	1.95
(Decrease)/ increase in other current liabilities		(58.05)	31.35
<b>Cash used in operations</b>		<b>962.59</b>	<b>1,148.35</b>
Income taxes paid/ TDS (net)		57.89	(193.86)
<b>Net cash used in operating activities (A)</b>		<b>1,020.48</b>	<b>954.49</b>
<b>B. Cash flows from investing activities</b>			
Payment for Purchase of property plant equipment (Including Capital advance & Work in Progress)		(832.23)	(391.97)
(Increase)/Decrease in other bank balances		(0.78)	1,774.29
Interest income received		183.95	140.90
<b>Net cash provided by/ (used in) investing activities</b>		<b>(649.06)</b>	<b>1,523.22</b>
<b>C. Cash flows from financing activities</b>			
Repayment of borrowings		-	-
Interest paid		-	-
<b>Net cash provided by financing activities (C)</b>		<b>-</b>	<b>-</b>
<b>Net increase/ (decrease) in cash and cash equivalents during the year( A+B+C)</b>		<b>371.42</b>	<b>2,477.71</b>
Cash and cash equivalents at the beginning of the year		2,657.51	181.57
Add/(less): exchange (loss)/gain on cash and cash equivalents		-	(1.77)
<b>Cash and cash equivalents at the end of the year</b>		<b>3,028.93</b>	<b>2,657.51</b>
<b>Cash and cash equivalents include</b>			
Balances with banks in current accounts		178.44	57.13
Deposits with original maturity of less than 3 months		2,850.00	2,600.00
Cash on hand		0.49	0.38
		<b>3,028.93</b>	<b>2,657.51</b>



## Notes:

1. The Statement of audited standalone financial results for the quarter and year ended March 31, 2026, is drawn up in accordance with the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which was reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 29, 2026. The Statutory Auditors of the Company have expressed an unmodified audit opinion.
2. The above results have been prepared in accordance with the recognition and measurement requirements of Indian Accounting Standards ("Ind AS") notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011, were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters, on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8<sup>th</sup> June 2022 and Long Form Standing certificate dated 15<sup>th</sup> June 2022 respectively, received from the concerned authorities.

Winding up order for Zenotech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI are pending.

Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results are no longer applicable.


5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
6. During the FY 2023-24, the Company has registered under Amnesty Scheme for one time settlement of default in export obligation by "Advance authorization and EPCG scheme" as notified by DGFT and request has been filed for Export Obligation Discharge Certificate (EODC). Out of 14 EPCG licenses approved under the scheme, 12 licenses were already settled as of March 31, 2025. During the quarter ended September 30, 2025, the Company received EODC in respect of 1 license and settled the liability in respect thereof. Accordingly, the Company has reversed the excess provision of Rs. 4.97 lakhs pursuant to crystallization of the liability and the same has been reported as Exceptional item in statement of unaudited financial results in previous quarter.
7. The Company as on October 25, 2025, filed an application to exercise the option to pay concessional rate of income tax under section 115BAA (5) of the Income Tax Act 1961 for the AY 2025-26 and accordingly, the tax liabilities has been reworked for the AY 2025-26 and accounting adjustment amounting to Rs. 190.49 lakhs has been taken in quarter and period ended September 30, 2025, and shown under Adjustment of tax relating to earlier period in statement of unaudited financial results. Additionally, the Company has reversed:
  - the MAT Credit entitlement amounting to Rs. 187.47 lakhs;
  - the deferred tax on unabsorbed additional depreciation amounting to Rs. 157.82 lakhs and charged to statement of profit and loss.

8. During the current quarter, the Company reversed Rs.58.84 lakhs towards MAT payable for FY 2023-24 pursuant to the assessment order received. Further, the Company has recognized a charge of Rs.48.93 lakhs, disclosed under adjustment of tax relating to earlier periods, net of income tax refund receivables and demand raised in the assessment orders for FY 2016-17 to FY 2022-23.
9. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing Labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave.

The Company has assessed the financial implications of these changes which has resulted in increase in gratuity and leave encashment liability arising out of past service cost by Rs. 24.48 lakhs. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as "Exceptional Item" in the Statement of Profit and Loss for the year ended March 31, 2026.

The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.
10. The Company has only one reportable segment, i.e. Pharmaceuticals.
11. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman of the Board meeting  
DIN-01219312

Place: New Delhi  
Date: April 29, 2026

**Independent Auditor's Review Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
**The Board of Directors**  
**Zenotech Laboratories Limited**

**Report on audit of Standalone Financial Results**

1. We have audited the accompanying statement of quarterly and year to date standalone financial results of Zenotech Laboratories Limited (the "Company") for the quarter and year ended March 31, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026, and for the year ended March 31, 2026.

**Basis of Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion



**Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process

**Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**

1. The financial results of the Company for the quarter and year ended March 31, 2025, included in the accompanying Statement as comparative financial information, were reviewed/audited by the previous auditors, who expressed an unmodified conclusion/opinion on those financial results vide their report dated April 25, 2025. Our conclusion on the Statement is not modified in respect of this matter.

(THIS SPACE HAS BEEN LEFT INTENTIONALLY BLANK)



# **G S K A & Co.**

**Chartered Accountants**

2. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by previous auditors for the quarter ended June 30, 2025 and by us for the quarter ended September 30, 2025 and December 31, 2025, as required under the Listing Regulations.

For **G S K A & Co.**

Chartered Accountants

**ICAI Firm Registration Number: 147093W**



per **Ganesh Gaikwad**  
Partner

Membership Number: 136512

UDIN: 26136512LEVRNF4962



Date: April 29, 2026

Place: Pune



# zenotech

CIN: L27100TG1989PLC010122

**ZENOTECH LABORATORIES LIMITED**

**Registered Office & Factory:**

Survey No.250 -252,

Turkapally Village, Genome Valley Road,

Shamirpet Mandal

Medchal-Malkajgiri Dist.,

Turkapallyadaram

Hyderabad - 500 101 Telangana, India.

Tel: +91 90320 44584/ 585

Email: info@zenotech.co.in

www.zenotechlab.com

Date: April 29, 2026

**BSE Limited**

Corporate Relationship Dept.,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

**Scrip Code: 532039**

Dear Sir/ Ma'am,

**Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

I, Poly K.V., Chief Financial Officer of Zenotech Laboratories Limited, having registered office at Survey No.250-252, Turkapally Village, Genome Valley Road, Shamirpet Mandal, Medchal-Malkajgiri District, Hyderabad – 500 101, hereby declare that the Statutory Auditors of the Company, M/s. **G S K A & Co.**, Chartered Accountants (Firm Registration No. 147093W) have issued an Audit Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the financial year ended March 31, 2026.

Kindly take this declaration on your record.

For **ZENOTECH LABORATORIES LIMITED**

Poly K.V.

**Chief Financial Officer**

